RxSight, Inc. (RXST) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025. RxSight, Inc. is a commercial-stage medical technology company focused on the premium cataract surgery market. Its proprietary RxSight system consists of the Light Adjustable Lens (LAL) and the Light Delivery Device (LDD), allowing doctors to customize and optimize patient vision post-surgery. The company operates primarily in the U.S. with regulatory approvals in Europe, Canada, Mexico, Singapore, Australia, and South Korea. As of year-end 2025, the company had an installed base of 1,134 LDDs and had implanted approximately 300,000 LALs since inception.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $134,479 | $139,927 | (3.9)% |
| Gross Profit | $103,009 | $98,943 | 4.1% |
| Gross Margin | 76.6% | 70.7% | +590 bps |
| Operating Loss | $(48,191) | $(36,858) | 30.7% increase |
| Net Loss | $(38,944) | $(27,455) | 41.8% increase |
| Cash & Short-Term Investments | $228,128 | $237,223 | N/A |
| Accumulated Deficit | $(661,039) | $(622,095) | N/A |
Revenue Composition (2025): LAL sales were $108.1 million (80% of revenue), LDD sales were $20.7 million (15%), and Service/Accessories were $5.7 million (4%).
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by $5.5 million (3.9%) primarily due to a 47% drop in LDD unit sales (163 units sold in 2025 vs. 305 in 2024). This was attributed to slower adoption of the technology by practices.
- LAL Volume Growth: Despite the LDD decline, LAL sales volume increased by 11,560 units (12%) due to the larger installed base driving recurring revenue.
- Margin Expansion: Gross margin improved significantly to 76.6% from 70.7%, driven by a favorable product mix shift toward higher-margin LAL consumables.
- Expense Increases: Operating expenses rose by $15.4 million (11.3%). Selling, General, and Administrative (SG&A) expenses increased by $11.2 million due to higher marketing study costs, new customer acquisition costs, and stock-based compensation. R&D expenses increased by $4.2 million.
- Commercial Realignment: The company reorganized its U.S. commercial structure, unifying LAL sales and clinical support into a single "Customer Success Organization" to drive utilization growth.
Guidance, Outlook, and Risks
Outlook: Management believes current cash, cash equivalents, and short-term investments ($228.1 million) are sufficient to fund operations for at least the next 12 months. The company does not anticipate the need to raise additional capital to reach profitability but may opportunistically seek capital to support expansion. The focus remains on increasing LAL utilization per installed LDD and expanding the installed base.
Key Risks and Contingencies:
- Legal Proceedings: The company is facing consolidated securities class action litigation (In re RxSight Securities Litigation) and shareholder derivative actions alleging false statements regarding product demand and financial guidance. The company denies these allegations.
- Profitability: The company has a history of net losses and expects to continue incurring losses in the near future as it invests in commercial expansion and R&D.
- Supply Chain: Reliance on single and sole-source suppliers for critical components creates vulnerability to supply disruptions and price fluctuations.
- Regulatory: Ongoing compliance with FDA Quality Management System Regulation (QMSR) and international regulations is required; failure to comply could result in recalls or shutdowns.
Investor Verification Checklist
- LDD Adoption Rate: Verify the trajectory of new LDD installations, as the 47% decline in 2025 is a critical indicator of market acceptance.
- Utilization Metrics: Monitor "LALs implanted per installed LDD" to assess the success of the new Customer Success Organization strategy.
- Litigation Status: Track developments in the consolidated securities class action and derivative suits, as adverse outcomes could result in significant financial liability.
- Cash Burn Rate: Confirm the sustainability of the $228 million cash position against the current operating loss of ~$48 million annually.
- Competitive Landscape: Assess market share trends against major competitors (Alcon, Johnson & Johnson) in the premium IOL segment.